Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations
Hims & Hers Health reported Q3 2026 revenue of $890.4M, meeting estimates, but missed EPS and EBITDA expectations. Full-year guidance fell short, with Q4 revenue and FY EBITDA projected below consensus. Operating and free cash flow margins declined, while customer count dropped to 2.79M.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered guidance are likely to trigger a sell‑off in HIMS shares, with potential spillover to other telehealth stocks.
Market read
The report provides fresh, material information that can affect trading decisions for HIMS and related health‑tech equities.
What to watch
Recent cost‑saving initiatives and upcoming product launches could offset short‑term earnings weakness.
Background
Hims & Hers Health reported Q3 2026 results with revenue essentially flat to estimates but a GAAP EPS loss versus a modest profit expectation, and guidance that fell short of consensus.
Ticker impact
Q3 2026 results missed revenue and EPS estimates and full-year guidance fell short of expectations.
downward pressure as market prices in the guidance shortfall
Both revenue and EPS were below consensus and guidance for Q4 and full year is below expectations, prompting a sell-off.
Market effects
Telehealth and digital health stocks may face broader scrutiny after the miss.
U.S. market sentiment could be dampened in the health‑tech segment.
Limited to investors tracking U.S. digital health equities.
Counterpoint
The miss may be temporary; long‑term growth prospects remain strong as the company expands its subscription base.
Key entities
- companyHims & Hers Health
U.S.-listed telehealth provider (NYSE:HIMS).
